The Retina Case Forum Webinar Series is an interactive web-based virtual meeting place for healthcare practitioners to review current concepts within retina. Each live webinar allows for peer-to-peer presentation with the creation of a comprehensive differential diagnosis, the interpretation of the results of diagnostic tests, and an exploration of the potential therapeutic options by identifying the advantages and drawbacks of each approach. Pre and post testing will allow for meaningful recognition of educational goals. The discussions will be of interest to retina specialists, comprehensive ophthalmologists, residents and fellows in training, and allied health professionals.

Diabetic Retinopathy Case Presentations

  • Treatment of DME with Anti-VEGF – Lessons Learned from Recent Clinical Trials

    Andrew P. Schachat, MD
  • Treatment of Diabetic Retinopathy in the Setting of DME

    Michael S. Ip, MD
  • Diabetic Retinopathy Session - Q&A

    Michael S. Ip, MD
Launch Date

April 27, 2016

Expiration Date

April 27, 2017

Estimated Time to Complete

1 Hour

Hardware/Software Needed to Participate

High speed internet access

Target Audience

This activity is designed to meet the educational need of retina specialists, comprehensive ophthalmologists, residents and fellows in training , and allied healthcare professionals involved in the care of patients with retinal diseases such as diabetic retinopathy.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Explore the use of anti-vascular endothelial growth factor (VEGF) for the treatment of delayed response in the setting of diabetic macular edema (DME)
  • Provide mechanisms for identification of delayed treatment response in DME and propose alternative pathways for treatment including long acting steroid therapies
Method of Participation

In order to receive credit, participants should watch the entire video. Statements of credit will be awarded upon successful completion of the post test and online evaluation/claim credit form. If you have questions about this CME activity, please contact AKH Inc. at


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AKH Inc., Advancing Knowledge in Healthcare and MCME Global, Inc. AKH Inc., Advancing Knowledge in Healthcare is accredited by the ACCME to provide continuing medical education for physicians.

AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty Disclosures

Michael S. Ip, MD

  • Consultant: Boehringer Ingelheim; Omeros; Quark; ThromboGenics NV

Andrew P. Schachat, MD

  • Consultant: AnGes
Planner Disclosures

Dorothy Caputo, MA, BSN, RN- CE Director of Accreditations

  • Nothing to Disclose

MCME Global Staff and Planners

  • Nothing to Disclose

AKH Staff and Planners

  • Nothing to Disclose
Commercial Support

This activity is supported by and educational grant from: Alcon, Inc.; Alimera Sciences; Allergan; Carl Zeiss; Optos; Regeneron Pharmaceuticals, Inc.; Santen Pharmaceutical


It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are resolved by AKH prior to accreditation of the activity and may include any of or combination of the following: attestation to non-commercial content; notification of independent and certified CME/CE expectations; referral to National Author Initiative training; restriction of topic area or content; restriction to discussion of science only; amendment of content to eliminate discussion of device or technique; use of other author for discussion of recommendations; independent review against criteria ensuring evidence support recommendation; moderator review; and peer review.

Disclosure of Unlabeled Use of Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant’s misunderstanding of the content.

Jointly provided by AKH Inc., Advancing Knowledge in Healthcare and MCME Global, Inc.

Advancing Knowledge in Healthcare    mcme-logo

This activity is supported by educational grants from:

Alimera Sciences
Regeneron Pharmaceuticals, Inc.
Santen Pharmaceutical


Diabetic Retinopathy Case Presentation Pre-Questions

Please answer the following pre-questions before moving on to the webinar presentation.

First Name*
Last Name*

Diabetic Retinopathy

Progresses along a scale developed by the ETDRS
Can be reversed at all levels by PRP
Was demonstrated to have high rates of spontaneous regression without treatment in Protocol S
Was demonstrated to stabilize using both doses (0.5mg and 0.3mg) in Protocol S

Which of the following are true concerning repeated anti-VEGF injections for diabetic retinopathy?

They have been demonstrated to result in regression of diabetic retinopathy level
They have been demonstrated to result in stabilization of diabetic retinopathy level
They have been demonstrated to result in a reduced need for PPV compared with PRP
They have been demonstrated to result in less visual field loss compared with PRP
All of the above

Regarding the Protocol T one year outcomes, which is true?

At one year, intravitreal triamcinolone showed the best efficacy
Aflibercept performed best for subjects 20/50 or worse at baseline
The mean number of injections in year 1 was 5

Regarding the Protocol T two year outcomes, which is true?

All 3 anti-VEGF groups showed VA improvement from baseline to 2 years with an increased number of injections in year 2
Visual acuity outcomes were similar all 3 groups for eyes with better baseline VA
All 3 groups overall at two years had a mean vision increase of 20 letters